- Home
- AVNT vs VKTX Comparison
AVNT vs VKTX Comparison
Compare AVNT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNT | VKTX |
|---|---|---|
| Founded | 1927 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1993 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AVNT | VKTX |
|---|---|---|
| Price | $36.15 | $30.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $45.29 | ★ $87.07 |
| AVG Volume (30 Days) | 790.5K | ★ 3.3M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $3,246,100,000.00 | N/A |
| Revenue This Year | $2.24 | N/A |
| Revenue Next Year | $2.41 | N/A |
| P/E Ratio | $29.83 | ★ N/A |
| Revenue Growth | ★ 1.03 | N/A |
| 52 Week Low | $27.48 | $18.92 |
| 52 Week High | $44.78 | $43.15 |
Technical Indicators
Market Signals| Indicator | AVNT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 38.27 |
| Support Level | $36.37 | $32.42 |
| Resistance Level | $37.77 | $34.99 |
| Average True Range (ATR) | 1.03 | 1.92 |
| MACD | 0.10 | -0.13 |
| Stochastic Oscillator | 74.38 | 12.59 |
Price Performance
Historical ComparisonAbout AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.